Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose

Journal of Clinical Oncology

Volumn 14, Issue 6, 1996, Pages 1848-1857

  Avril, N ^a   Dose, J ^a   Janicke F ^a   Bense, S ^a   Ziegler, S ^a   Laubenbacher, C ^a   Romer W ^a   Pache, H ^a   Herz, M ^a   Allgayer, B ^a   Nathrath, W ^a   Graeff, H ^a   Schwaiger, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BREAST TUMOR; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMAGE ANALYSIS; IMAGE ENHANCEMENT; MAJOR CLINICAL STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

EID: 8944242605     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.6.1848     Document Type: Article

References (50)

1. Chu KC, Smart CR, Tarone RE: Analyses of breast cancer mortality and stage distribution by age for the health insurance plan clinical trial. J Natl Cancer Inst 80:1125-1132, 1988
2. Kopans DB, Meyer JE, Sadowsky N: Breast imaging. N Engl J Med 310:960-967, 1984
3. Heywang SH, Wolf A, Pruss E, et al: MR imaging of the breast with Gd-DTPA: Use and limitations. Radiology 171:95-103, 1989
4. Egan RL, Egan KL: Detection of breast carcinoma: Comparison of automated water-path whole-breast sonography, mammography, and physical examination. AJR 143:493-497, 1984
5. Hermann G, Janus C, Schwartz IS, et al: Nonpalpable breast lesions: Accuracy of prebiopsy mammographic diagnosis. Radiology 165:323-326, 1987
6. Jackson VP: The role of ultrasound in breast imaging. Radiology 177:305-311, 1990
7. Gilles R, Guinebretière J-M, Lucidarme O, et al: Nonpalpable breast tumors: Diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology 191:625-631, 1994
8. Francheschi D, Crowe J, Zollinger R, et al: Biopsy of the breast for mammographically detected lesions. Gynecol Obstet 171:449-455, 1990
9. Strauss LG, Conti PS: The applications of PET in clinical oncology. J Nucl Med 32:623-648, 1991
10. DiChiro G: Positron emission tomography using (18-F) fluorodeoxyglucose in brain tumors; A powerful diagnostic and prognostic tool. Invest Radiol 22:360-371, 1986
11. Rege S, Maass A, Chaiken L, et al: Use of positron emission tomography with fluorodeoxyglucose in patients with extracranial head and neck cancers. Cancer 73:3047-3058, 1994
12. Laubenbacher C, Saumweber D, Wagner-Manslau C, et al: Comparison of fluorine-18-fluorodeoxyglucose PET, MRI and endoscopy for staging of head and neck squamous-cell carcinomas. J Nucl Med 36:1747-1757, 1995
13. Wahl RL, Quint LE, Greenough RL, et al: Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: Preliminary prospective evaluation. Radiology 191:371-377, 1994
14. Lewis P, Griffin S, Marsden P, et al: Whole-body F-18-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancer. Lancet 344:1265-1266, 1994
15. Bares R, Klever P, Hauptmann S, et al: F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology 192:79-86, 1994
16. Okazumi S, Isono K, Enomoto K, et al: Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: Characterization of tumors and assessment of effect of treatment. J Nucl Med 33:333-339, 1992
17. Okada J, Yoshikawa K, Itami M, et al: Positron emission tomography using fluorine-18-fluorodeoxyglucose in malignant lymphoma: A comparison with proliferative activity. J Nucl Med 33:32-329, 1992
18. Griffeth LK, Dehdashti F, McGuire AH, et al: PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology 182:185-194, 1992
19. Adler LP, Blair HF, Makley JT, et al: Noninvasive grading of musculoskeletal tumors using PET. J Nucl Med 32:1508-1512, 1991
20. Hawkins RA, Hoh CK: PET FDG studies in oncology. Nucl Med Biol 21:739-747, 1994
21. Kubota K, Matsuzwana T, Amemiya A, et al: Imaging of breast cancer with (18-F)fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 13:1097-1098, 1989
22. Wahl RL, Cody RL, Hutchins GD, et al: Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology 179:765-770, 1991
23. Tse YN, Hoh CK, Hawkins RA, et al: The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 11:359-377, 1992
24. Nieweg ON, Kim EE, Wong W-H, et al: Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 71:3920-3925, 1993
25. Adler LP, Crowe JP, Al-Kaisi NK, et al: Evaluation of breast masses and axillary lymph nodes with (F-18) 2-deoxy-2-fluoro-D-glucose PET. Radiology 187:743-750, 1993
26. Harnacher K, Coenen HH, Stöcklin G: Efficient stereospecific synthesis of nocarrier-added 2-(F-18)-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med 27:235-238, 1986
27. Hoffmann EJ, Huang S, Phelps ME: Quantitation in positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 3:299-308, 1979
28. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377, 1957
29. Gerdes J, Schwab U, Lemke H, et al: Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31:13-20, 1983
30. Shintaku P, Said JW: Detection of estrogen receptors with monoclonal antibodies in routinely processed formalin-fixed paraffin sections of breast carcinoma. Am J Clin Pathol 87:161-167, 1987
31. Remmele W, Stegner HE: Vorschlag zur einheitlichen Definition eines Immunreaktiven Score (IRS) für den immunhistochemischen Östrogenrezeptor-Nachweis (ER-ICA) im Mammakarzinomgewebe. Pathologe 8:138-140, 1987
32. Hanley JA, McNeil BJ: The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143:29-36, 1982
33. Amrein PC, Larson SM, Wagner HNJ: An automated system for measurement of leukocyte metabolism. J Nucl Med 15:352-355, 1975
34. Tahara T, Ichiya Y, Kuwabara Y: High-fluorodeoxyglucose uptake in abdominal abscesses: A PET study. J Comp Assist Tomogr 13:829-831, 1989
35. Platz EF, Lowe VJ, Hoffmann JM, et al: Focal pulmonary abnormalities: Evaluation with F-18-fluorodeoxyglucose PET scanning. Radiology 188:487-490, 1993
36. Lewis P, Salama A: Uptake of fluorine-18-fluorodeoxyglucose in sarcoidosis. J Nucl Med 35:1647-1649, 1994
37. Kubota R, Yamada S, Kubota K, et al: Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulation tissue studied by microautoradiography. J Nucl Med 33:1972-1980, 1992
38. Rosenberg AL, Schwartz GF, Feig AS, et al: Clinically occult breast lesions; Localisation and significance. Radiology 162:167-170, 1987
39. Elmore JG, Wells CK, Lee CH, et al: Variability in radiologists interpretation of mammograms. N Engl J Med 331:1493-1499, 1994
40. Heywang-Köbrunner SH, Haustein J, Pohl C, et al: Contrast-enhanced MR imaging of the breast: Comparison of two different doses of gadopentetate dimeglumine. Radiology 191:639-646, 1994
41. Cady B, Stone MD, Wayne J: New therapeutic possibilities in primary invasive breast cancer. Ann Surg 218:338-349, 1993
42. Kao CH, Wang SJ, Liu TJ: The use of technetium-99m methoxyisobutylisonitrile breast scintigraphy to evaluate palpable breast masses. Eur J Nucl Med 21:432-436, 1994
43. Khalkhali I, Mena I, Jouanne E, et al: Prone scintimammography in patients with suspicion of carcinoma of the breast. J Am Coll Surg 78:491-497, 1994
44. Khalkhali I, Cutrone J, Mena I, et al: Technetium-99m-sestamibi scintimammography of breast lesions: Clinical and pathological follow-up. J Nucl Med 36:1784-1789, 1995
45. Taillefer R, Robidoux A, Lambert R, et al: Technetium-99m-sestamibi prone scintimammography to detect primary breast cancer and axillary lymph node involvement. J Nucl Med 36:1758-1765, 1995
46. Hoh CK, Hawkins RA, Glaspy JA, et al: Cancer detection with whole-body PET using 2-[18-F]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr 17:582-589, 1993
47. Lindholm P, Minn H, Leskinen-Kallio S, et al: Influence of the blood glucose concentration on FDG uptake in a cancer PET study. J Nucl Med 34:1-6, 1993
48. DiChiro G, DeLaPaz RL, Brooks RA, et al. Glucose utilization of cerebral gliomas measured by (18-F) fluorodeoxyglucose and positron emission tomography. Neurology 32:1323-1329, 1982
49. Higashi K, Anaira CC, Wahl RL: Does FDG uptake measure proliferative activity of human cancer cells? In vitro comparison with DNA flow cytometry and tritiated thymidine uptake. J Nucl Med 34:414-419, 1993
50. Leskinen-Kallio S, Nagren K, Lehikoinen P, et al: Uptake of 11C-methionine in breast cancer studied by PET. An association with the size of S-phase fraction. Br J Cancer 64:1121-1124, 1991